XML 72 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 80,428 $ 140,418
Marketable securities 282,046 259,715
Interest receivable 682 375
Accounts receivable 36,909 4,673
Prepaid expenses and other current assets 5,408 5,340
Total current assets 405,473 410,521
Marketable securities, non-current 21,832 0
Property and equipment, net 29,926 78,723
Intangible assets 53,156 54,243
Goodwill 39,273 40,044
Operating lease right-of-use assets 77,289 0
Other non-current assets 9,067 3,364
Non-current restricted cash 1,500 3,500
Total assets 637,516 590,395
Current liabilities:    
Accounts Payable and Accrued Liabilities, Current 17,556 21,457
Accrued compensation and employee benefits 13,605 9,490
Deferred revenues 38,711 47,564
Total current liabilities 69,872 78,511
Deferred revenues, non-current 81,432 108,273
Long-term portion of lease liabilities 41,192 0
Long-term portion of lease liabilities   27,689
Deferred income tax 6,570 6,705
Other non-current liabilities 5,711 1,960
Total liabilities 204,777 223,138
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued or outstanding 0 0
Common stock, $0.01 par value; 160,000,000 shares authorized, 115,972,708 and 102,187,471 shares issued and outstanding at December 31, 2019 and 2018, respectively 1,160 1,022
Additional paid-in capital 1,090,828 929,632
Accumulated deficit (656,985) (562,696)
Accumulated other comprehensive loss (2,449) (1,440)
Total Sangamo Therapeutics, Inc. stockholders' equity 432,554 366,518
Non-controlling interest 185 739
Total stockholders' equity 432,739 367,257
Total liabilities and stockholders' equity $ 637,516 $ 590,395